证券日报网讯 1月6日，健康元在互动平台回答投资者提问时表示，公司流感创新药壹立康胶囊剂型已 上市，针对儿童的干混悬剂剂型目前已进入三期临床试验阶段。相较于胶囊剂型，干混悬剂更适配儿童 的用药特点与吞咽需求，服用便捷性更佳、依从性更高，更贴合儿科临床用药场景。公司正全力推进该 剂型的临床研究及后续上市申报各项工作，相关重大进展将严格按照规定及时履行信息披露义务。 （文章来源：证券日报） ...

Core Viewpoint - The company, Jibeier, announced that it will disclose the number of shareholders in its 2025 annual report to ensure fairness in information disclosure [1] Group 1 - The company responded to investor inquiries regarding the number of shareholders at the end of the reporting period [1] - The information about the number of shareholders is considered a periodic report disclosure requirement [1] - The company aims to maintain transparency and fairness in its information disclosure practices [1]

（文章来源：证券日报） 证券日报网讯 1月6日，健康元在互动平台回答投资者提问时表示，公司始终严格遵守信息披露相关法 律法规，目前不存在应披露而未披露的重大信息，二级市场股价波动受宏观经济环境、行业政策导向、 市场情绪、资金流向等多重因素综合影响；流感药壹立康已于12月底在阿里健康、京东健康等平台上线 销售，终端定价综合考量了市场竞争格局、产品定位及相关政策要求，后续商业化推广工作正有序推 进；公司估值是市场各方基于行业发展前景、公司核心竞争力、经营基本面等多重因素形成的综合判 断，公司始终聚焦主业，持续推进创新转型，以扎实的研发成果和经营业绩为投资者创造长期价值；股 份回购事项需结合公司经营状况、资金安排及发展战略等综合考量，后续若有相关计划，公司将严格按 照监管规定履行审议程序及信息披露义务。 ...

宏源药业首次公开发行股票募集资金总额为人民币236,286.00万元，扣除发行费用后募集资金净 额为219,584.37万元。该公司最终募集资金净额比原计划多154,511.37万元。宏源药业于2023年3月14 日披露的招股说明书显示，该公司拟募集资金65,073.00万元，用于研发中心及多功能试验车间项目、 抗病毒原料药及中间体项目、年产25亿片（粒）高端制剂车间项目。 宏源药业首次公开发行股票的发行费用总额为16,701.63万元，其中保荐及承销费用13,931.96万 元。 (责任编辑：徐自立) 中国经济网北京1月6日讯 宏源药业(301246.SZ)今日收报24.11元，跌幅4.44%。该股目前处于破 发状态。 宏源药业于2023年3月20日在深交所创业板上市，公开发行股票4,725.72万股，发行价格为50.00 元/股，保荐机构（主承销商）为民生证券股份有限公司（现为国联民生证券股份有限公司），保荐代 表人为谢广化、肖继明。 上市首日，宏源药业盘中创下股价高点45元，此后股价震荡下跌。 ...

Group 1: Market Performance - The chemical pharmaceutical sector increased by 5.36% on January 6, with Yuyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up 1.5%, while the Shenzhen Component Index closed at 14022.55, up 1.4% [1] Group 2: Individual Stock Performance - Yuyuan Pharmaceutical (688658) closed at 26.85, up 7.83% with a trading volume of 168,800 shares and a transaction value of 456 million [1] - Other notable gainers included Bibete (688759) at 34.50, up 6.15%, and Qianyan Bio (688221) at 22.40, up 5.66% [1] Group 3: Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.064 billion from institutional investors, while retail investors saw a net inflow of 617 million [2] - The sector's overall fund flow indicates a mixed sentiment, with retail investors actively participating despite institutional outflows [2][3]

每经AI快讯，有投资者在投资者互动平台提问：公司流感创新药壹立康胶囊版已经上市了，请问儿童 版什么时候可以上市？ 健康元（600380.SH）1月6日在投资者互动平台表示，尊敬的投资者，您好！公司流感创新药壹立康胶 囊剂型已上市，针对儿童的干混悬剂剂型目前已进入三期临床试验阶段。相较于胶囊剂型，干混悬剂更 适配儿童的用药特点与吞咽需求，服用便捷性更佳、依从性更高，更贴合儿科临床用药场景。公司正全 力推进该剂型的临床研究及后续上市申报各项工作，相关重大进展将严格按照规定及时履行信息披露义 务，敬请关注。感谢您的关注与支持！ （文章来源：每日经济新闻） ...

证券日报网讯1月6日，易明医药（002826）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东数为18111户。 ...

Core Viewpoint - The company, Pro Pharmaceutical (000739), has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The collaboration aims to expand the company's CDMO business and enhance its competitiveness in the CDMO sector [1]

Group 1 - The core viewpoint of the news is that Zhejiang Huahai Pharmaceutical Co., Ltd. has undergone a site inspection by its sponsor, Zheshang Securities, which found that the company is operating well in terms of corporate governance, internal control, and compliance with regulations [1][12] Group 2 - The site inspection was conducted on December 30, 2025, and involved reviewing the company's governance documents, internal control systems, and financial practices [3][4] - The inspection confirmed that the company has a complete governance structure and that its internal control systems are effectively implemented [2][4] - The company has maintained independence from its controlling shareholders and has not engaged in any improper transactions with related parties [4][5] Group 3 - The use of raised funds was found to be compliant, with all funds stored in designated accounts and no evidence of misuse or unauthorized changes in fund allocation [5][6] - There were no violations related to external guarantees, related transactions, or significant external investments during the inspection period [5][6] Group 4 - The company's operational status remains stable, with no significant adverse changes in its business model or structure [6][12] - The company is advised to continue enhancing its corporate governance and risk management practices to ensure accurate and complete information disclosure [8]

Core Viewpoint - New Nuo Wei's stock price has shown fluctuations with a recent increase, while the company faces challenges in profitability despite revenue growth [1][2]. Financial Performance - As of January 6, New Nuo Wei's stock price was 38.20 CNY per share, with a market capitalization of 53.655 billion CNY [1]. - For the period from January to September 2025, the company achieved a revenue of 1.593 billion CNY, representing a year-on-year growth of 7.71%, but reported a net profit loss of 24.049 million CNY, a decrease of 117.26% compared to the previous year [2]. Shareholder Information - As of December 10, the number of shareholders increased to 24,300, up by 4.36%, while the average circulating shares per person decreased by 4.17% to 57,704 shares [2]. - Cumulative cash dividends since the A-share listing amount to 651 million CNY, with 500 million CNY distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 17.7822 million shares, a decrease of 3.2169 million shares from the previous period [3]. - Other notable shareholders include China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A, with varying changes in their holdings [3].